Technical Abstract: Worldwide, reports document the increasing frequency of methicillin resistant Staphylococcus aureus (MRSA) infections. Other human pathogens are recognized as unresponsive to antibiotics of last resort. These previously treatable infections now account for increased numbers of human disease and deaths following severe surface wounds or exposure to nosocomial sources. This report documents a novel set of bacteriocins capable of killing MRSA and other refractile, antibiotic-resistant bacterial infections. The minimal inhibitory concentration (MIC; 'g/ml) of bacteriocins OR-7, E 50-52 and nisin and, 20 selected antibiotics were tested against 15 antibiotic resistant clinical isolates. Very low concentrations (generally, < 1 µg/ml) of OR-7 and E 50-52 killed each of the antibiotic-resistant clinical isolates. These bacteriocins represent a novel alternative for treating clinical infections.